Q4 2024 Earnings Call Transcript March 10, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...
Coherus BioSciences, Inc. ( NASDAQ: CHRS) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaoker - SVP, ...
This is seen as a result of HLB's liver cancer drug "Livo-camrel combination therapy" being listed as a first-line treatment in the "Hepatocellular carcinoma diagnosis/treatment guidelines (HCC ...
National Health Commission Guidelines for the Diagnosis and Treatment of Primary Hepatocellular Carcinoma, and National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN ...
Shares of Hindustan Construction Company (HCC) Ltd gathered strong momentum in Monday's trade after its joint venture with in with Tata Projects Ltd (TPL) secured a Rs 2,191 crore contract for ...
The unit of AFP is ng/mL. With the advent of the immunotherapy era in oncology, researchers have held great expectations for immunotherapy-based adjuvant treatments in HCC. The IMbrave 050 study, as ...
HYDRINITY Accelerated Skin Science, the fastest growing professional skincare brand in the U.S., proudly unveils its newest category disruptor: ENCORE Body Hydrator. This transformative body treatment ...
Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback